On-Demand Virtual Conference

Due to social distancing and large group gathering restrictions, ACI’s Life Sciences IP Due Diligence changed its format from an in-person event to a live and interactive virtual conference. If you missed the conference, you can still purchase the recording and watch on your schedule. Watch from wherever you may be, access information delivered by our expert speaker faculty as you would at an onsite event.

Purchase Recording

This one-of-a-kind, interactive forum where top diligence leaders will discuss best practices and help you develop strategies for preparing for, conducting, and applying the results of the IP due diligence process.

Intellectual property is one of the most important assets a life sciences company has. As such, when engaging your team members in the buying, selling, licensing, distribution or franchising of IP, the need to engage in a meticulous and strategically timed IP due diligence review is essential to preventing a disappointing or even disastrous outcome.

ACI’s 4th Annual Life Sciences IP Due Diligence Summit is devoted to providing corporate and IP counsel with expert strategies for assessing, valuing and commercializing IP assets when conducting strategic IP due diligence which is essential to nearly every corporate transaction. Our esteemed speakers will provide insights on what to look for during the due diligence process, when to report findings, how to communicate effectively within and across teams, and when to adjust your expectations and decisions as the process proceeds.

Jennifer K. Gregory

Jennifer K. Gregory

Assistant General Patent
Counsel – IP Transactions

Eli Lilly and Company

Henry H. Gu

Henry H. Gu

Vice President, Chief IP Counsel
Akebia Therapeutics

  • Akebia Therapeutics
  • Akorn Pharmaceuticals
  • Boehringer Ingelheim USA Corporation
  • Cantel Medical
  • Eisai Inc.
  • Eli Lilly and Company
  • Flagship Pioneering
  • Genentech
  • Gilead Sciences
  • Merck
  • Novartis Pharmaceuticals
  • Omega Therapeutics
  • Pieris Pharmaceuticals
  • Roche
  • Sanofi
  • Takeda

In addition, this year’s event will shed light on COVID-19’s impact on biopharma deal making, patent strategies and valuation of IP assets, as well as how to effectively and successfully conduct a virtual IP due diligence analysis.

  • COVID-19’s Impact on Biopharma Deal Making and Valuation of IP Assets
  • Strategies for Performing a Robust Virtual/Remote IP Due Diligence Review
  • Conducting IP Due Diligence in Connection with Distressed Companies and Distressed Assets
  • Uncovering Red Flags in IP Ownership
  • Assessing the Impact of Government Funding Initiatives on IP Rights and IP Evaluation
  • Conducting IP Due Diligence for MedTech and AI
  • How New Developments at FDA are Impacting the IP Due Diligence Review Process
  • AMRI
  • Akin Gump Strauss Hauer & Feld LLP
  • Allergan plc
  • Arnold & Porter Kaye Scholer LLP
  • AtriCure Inc
  • Axinn Veltrop & Harkrider LLP
  • BA Ruskin Law LLC
  • BONWRx
  • Beck & Thomas
  • Biogen
  • Blaze Bioscience Inc
  • Boehringer Ingelheim GmbH
  • Boehringer Ingelheim International GmbH
  • Brammer Bio
  • Brinks Gilson & Lione
  • Cantor Colburn LLP
  • Carlson Caspers Vandenburgh Lindquist & Schuman PA
  • Centre for Drug Research and Development
  • Charles River Associates Inc
  • Choate Hall & Stewart LLP
  • Cipla Limited
  • Clark & Elbing LLP
  • Codiak BioSciences
  • DRI Capital Inc
  • Dentsply Sirona Inc
  • Dr. Reddys Laboratories
  • Drinker Biddle & Reath LLP
  • Duane Morris LLP
  • Eisai Inc
  • Evolve BioSystems
  • Finnegan Henderson Farabow Garrett & Dunner
  • Fish & Richardson
  • Fitzpatrick Cella Harper & Scinto
  • Foghorn Therapeutics
  • Forma Therapeutics Inc
  • Futuragene
  • Genentech Inc
  • Gibson Dunn & Crutcher LLP
  • Gilead Sciences
  • Green Griffith & Borg-Breen LLP
  • Heliae
  • Hikma Pharmaceuticals USA Inc
  • Houlihan Lokey
  • Hueschen & Sage PLLC
  • Immunogen Inc
  • Indivior Inc
  • Intellia Therapeutics Inc
  • Ipsen Bioscience Inc
  • Ironwood Pharmaceuticals Inc
  • Jazz Pharmaceuticals
  • Johnson-IP Strategy & Policy Consulting
  • Jounce Therapeutics Inc
  • KSQ Therapeutics Inc
  • King & Spalding LLP
  • Leason Ellis LLP
  • MEDRx
  • Marshall Gerstein & Borun LLP
  • Mayer Brown LLP
  • McDonnell Boehnen Hulbert & Berghoff LLP
  • Merchant & Gould
  • Merck & Co
  • MicroVention Inc.
  • Norris McLaughlin & Marcus P.A.
  • Novartis
  • Novartis Institutes For Biomedical Research
  • Novartis Pharmaceuticals
  • Obalon Therapeutics
  • Ohlandt Greely Ruggiero & Perle LLP
  • Paul Hastings LLP
  • Pearne & Gordon LLP
  • Pepper Hamilton LLP
  • Pieris Pharmaceuticals Inc
  • Porzio Bromberg & Newman P.C.
  • Purdue Pharma LP
  • Purdue Research Foundation
  • Regeneron Pharmaceuticals Inc
  • Roivant Sciences Inc
  • Ropes & Gray LLP
  • Rutgers Law School
  • Sarepta Therapeutics
  • Shire Pharmaceuticals
  • SmartPharm Therapeutics
  • Squire Patton Boggs Us LLP
  • Steptoe & Johnson LLP
  • Sterne Kessler Goldstein & Fox
  • Sun Pharmaceutical Industries Ltd
  • Taro Pharmaceutical Industries
  • Teva Pharmaceuticals
  • Transformative
  • US Court of Appeals for Federal Circuit
  • University of California
  • VBI Vaccines Inc
  • VLP Law Group LLP
  • Wave Life Sciences
  • Wilson Sonsini Goodrich & Rosati PC
Quote Icon

Unique high level sessions, good mix of in-house and outside counsel.

Quote Icon

Hearing from professionals involved in due diligence on a daily basis was very informative.

Quote Icon

Great panels, lots of diversity of practice, and lots of seasoned practitioners.

Quote Icon

The design of the event brought us all together along with room intimacy.

ACI’s Global Series of Life Sciences conferences bring together key sector stakeholders from around the globe to explore the most important trends impacting the many industries including pharmaceutical, biotechnology, medical device/diagnostics, and FDA-regulated consumer products. Our events cover every facet of legal and business relevance as well as controversy.
Learn More